Purdue Pharma (Canada)

Recent papers from Purdue Pharma (Canada)

1. Real-world all-cause healthcare resource utilization and costs among patients with interstitial cystitis/bladder pain syndrome in the United StatesJournal of Medical Economics · 2026
2. Greenhouse Evaluation of Napropamide and Pendimethalin for Suppression of Strawberry Daughter Plant Rooting and Runner Management ImplicationsWeed Technology · 2026
3. Structure-Activity Relationship Studies for 1,3,4-Thiadiazole-Based Bacterial Carbonic Anhydrase Inhibitors with In Vivo Efficacy against Drug-Resistant Neisseria gonorrhoeaeJournal of Medicinal Chemistry · 2026
4. Mitochondrial Ubiquitination as a Signaling Hub: Balancing Mitophagy, Inflammation, and Cell DeathBiochemistry · 2026
5. Abstract 4611: Small-molecule stabilization of non-native c-Myc multimer drives degradation using an IDP-targeting discovery platformCancer Research · 2026
6. O‐Silyl Codeine Analogues as Ligands for Opioid ReceptorsChemistrySelect · 2025
7. Management of Adolescents and Young Adults With Attention-Deficit/Hyperactivity DisorderThe Primary Care Companion For CNS Disorders · 2024
8. Inhibition of pathogenic bacterial carbonic anhydrases by monothiocarbamatesJournal of Enzyme Inhibition and Medicinal Chemistry · 2023
9. Current treatment of non-small cells lung cancer with EGFR mutation: first-line and management upon progressionRevisiones en cáncer · 2023
10. Analysis of Daily Sleep Diary Measures From Multilayer Extended-Release Methylphenidate (PRC-063) Studies in Children and Adults With ADHDJournal of Attention Disorders · 2022
11. Structure-activity relationship studies for inhibitors for vancomycin-resistant Enterococcus and human carbonic anhydrasesJournal of Enzyme Inhibition and Medicinal Chemistry · 2022
12. Coumarins effectively inhibit bacterial α-carbonic anhydrasesJournal of Enzyme Inhibition and Medicinal Chemistry · 2022
13. Dithiocarbamates effectively inhibit the α-carbonic anhydrase from Neisseria gonorrhoeaeJournal of Enzyme Inhibition and Medicinal Chemistry · 2021
14. Effect of a Multilayer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adolescents with Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Fixed-Dose, Placebo-Controlled Trial Followed by a 6-Month Open-Label Follow-UpJournal of Child and Adolescent Psychopharmacology · 2021
15. Efficacy and Safety of a Long-Acting Multilayer-Release Methylphenidate Formulation (PRC-063) in the Treatment of Adolescent Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind Clinical Trial with a 6-Month Open-Label ExtensionJournal of Child and Adolescent Psychopharmacology · 2021
16. Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Adult Laboratory Classroom Study of the Efficacy and Safety of PRC-063 (Extended-Release Methylphenidate) for the Treatment of ADHDJournal of Attention Disorders · 2021
17. Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label ExtensionCNS Drugs · 2021
18. The Transition from Small to Large Farms in Developing Economies: A Welfare AnalysisAmerican Journal of Agricultural Economics · 2021
19. Pharmacists’ knowledge, experiences and perceptions of treatments for attention-deficit/hyperactivity disorderCanadian Pharmacists Journal / Revue des Pharmaciens du Canada · 2021
20. Anion inhibition studies of the α-carbonic anhydrases from Neisseria gonorrhoeaeJournal of Enzyme Inhibition and Medicinal Chemistry · 2021